Literature DB >> 7537089

An expanded model of replicating human immunodeficiency virus reverse transcriptase.

B M Wöhrl1, C Tantillo, E Arnold, S F Le Grice.   

Abstract

Replication complexes containing wild-type and RNase H-deficient p66/p51 human immunodeficiency virus type 1 reverse transcriptase (HIV-1 RT) were analyzed by DNase I and S1 footprinting. While crystallography and chemical footprinting data demonstrate that 15-18 bases of primer and template occupy the DNA polymerase and RNase H active centers, enzymatic footprinting suggests that a larger portion of substrate is encompassed by the replicating enzyme. Independent of the position of DNA synthesis arrest, template nucleotides +7 to -23 and primer nucleotides -1 to -25 are nuclease resistant. On both DNA strands, position -20 remains accessible to DNase I cleavage, suggestive of an alteration in nucleic acid structure between exiting the RNase H catalytic center and leaving the C-terminal p66 domain. A model of HIV-1 RT containing an extended single-stranded template and duplex region was constructed on the basis of the structure of an RT/DNA complex. Mapping of footprint data onto this model shows consistency between biochemical and structural data, implicating a contribution from domains proximal to the catalytic centers.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7537089     DOI: 10.1021/bi00016a005

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  21 in total

1.  Stabilization of the U5-leader stem in the HIV-1 RNA genome affects initiation and elongation of reverse transcription.

Authors:  N Beerens; F Groot; B Berkhout
Journal:  Nucleic Acids Res       Date:  2000-11-01       Impact factor: 16.971

2.  Specific cleavages by RNase H facilitate initiation of plus-strand RNA synthesis by Moloney murine leukemia virus.

Authors:  Sharon J Schultz; Miaohua Zhang; James J Champoux
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

3.  Tighter binding of HIV reverse transcriptase to RNA-DNA versus DNA-DNA results mostly from interactions in the polymerase domain and requires just a small stretch of RNA-DNA.

Authors:  William P Bohlayer; Jeffrey J DeStefano
Journal:  Biochemistry       Date:  2006-06-20       Impact factor: 3.162

4.  Stable complexes formed by HIV-1 reverse transcriptase at distinct positions on the primer-template controlled by binding deoxynucleoside triphosphates or foscarnet.

Authors:  Peter R Meyer; Wiriya Rutvisuttinunt; Suzanne E Matsuura; Antero G So; Walter A Scott
Journal:  J Mol Biol       Date:  2007-03-12       Impact factor: 5.469

5.  Novel aptamer inhibitors of human immunodeficiency virus reverse transcriptase.

Authors:  Jeffrey J DeStefano; Gauri R Nair
Journal:  Oligonucleotides       Date:  2008-06

6.  Expression of an Mg2+-dependent HIV-1 RNase H construct for drug screening.

Authors:  Richard V Farias; Deborah A Vargas; Andres E Castillo; Beatriz Valenzuela; Marie L Coté; Monica J Roth; Oscar Leon
Journal:  Antimicrob Agents Chemother       Date:  2011-07-18       Impact factor: 5.191

7.  Determination of the site of first strand transfer during Moloney murine leukemia virus reverse transcription and identification of strand transfer-associated reverse transcriptase errors.

Authors:  D Kulpa; R Topping; A Telesnitsky
Journal:  EMBO J       Date:  1997-02-17       Impact factor: 11.598

Review 8.  Retroviral reverse transcriptases.

Authors:  Alon Herschhorn; Amnon Hizi
Journal:  Cell Mol Life Sci       Date:  2010-04-01       Impact factor: 9.261

Review 9.  What is the orientation of DNA polymerases on their templates?

Authors:  S H Hughes; Z Hostomsky; S F Le Grice; K Lentz; E Arnold
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

Review 10.  Reverse transcriptase in motion: conformational dynamics of enzyme-substrate interactions.

Authors:  Matthias Götte; Jason W Rausch; Bruno Marchand; Stefan Sarafianos; Stuart F J Le Grice
Journal:  Biochim Biophys Acta       Date:  2009-08-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.